Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas

Journal of Urology

Volumn 161, Issue 4, 1999, Pages 1359-1363

  Õzdemir, Enver ^b   Kakehi, Yoshiyuki ^a   Okuno, Hiroshi ^b   Yoshida, Osamu ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Matrix metalloproteinases; Superficial urothelial carcinomas; Tissue inhibitors of matrix metalloproteinase 1; Type IV collagen

Indexed keywords

COLLAGEN TYPE 4; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER STAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR;

EID: 0032867683     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61684-7     Document Type: Article

References (21)

1. Schapers, R. F., Pauwels, R. P., Havenith, M. G., Smeets, A. V., van den Brandt, P. A. and Bosman, F. T.: Prognostic significance of type IV collagen and laminin immunoreactivity in urothelial carcinomas of the bladder. Cancer, 66: 2583, 1990.
2. Parsons, S. L., Watson, S. A., Brown, P. D., Collins, H. M. and Steele, R. J. C.: Matrix metalloproteinases. Br J. Surg., 84: 160, 1997.
3. Özdemir, E., Kakehi, Y., Okuno, H., Habuchi, T., Okada, Y. and Yoshida, O.: Strong correlation of basement membrane degradation with p53 inactivation and/or mdm2 overexpression in superficial urothelial carcinomas. J. Urol., 158: 206, 1997.
4. Grant, G. M., Cobb, J. K., Castillo, B. and Klebe, R. J.: Regulation of matrix metalloproteinases following cellular transformation. J. Cell. Physiol., 167: 177, 1996.
5. Wirl G. and Frick, J.: Collagenase: a marker enzyme in human bladder cancer? Urol. Res., 7: 103, 1979.
6. Margulies, I. M., Hoyhtya, M., Evans, C., Stracke, M. L., Liotta, L. A. and Stetler-Stevenson, W. G.: Urinary type IV collagenase: evaluated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol. Biomarkers Prev., 1: 467, 1992
7. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A. and Balkwill, F.: Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365, 1993.
8. Gohji, K., Fujimoto, N., Komiyama, T., Fujii, A., Ohkawa, J., Kamidono, S. and Nakajima, M.: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer, 78: 2379, 1996.
9. Gohji, K., Fujimoto, N., Fujii, A., Komiyama, T., Ohkawa, J. and Nakajima, M.: Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res., 56: 3196, 1996.
10. Mostofi, F. K., Sobin, L. H. and Torloni, H.: Histological typing of urinary bladder tumors. Geneva: World Health Organization, International Classification of Tumors No. 10, pp. 9-35, 1973.
11. Hermanek, P. and Sobin, L. H.: TNM Classification of Malignant Tumors. 4th ed., Geneva: International Union Against Cancer (UICC), 1987.
12. Fujimoto, N., Hosokawa, N., Iwata, K., Shinya, T., Okada, Y. and Hayakawa, T.: A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin. Chim. Acta, 231: 79, 1994.
13. Kodama, S., Iwata, K., Iwata, H., Yamashita, K. and Hayakawa, T.: Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J. Immunol. Methods, 127: 103, 1990.
14. Arii, S., Mise, M., Harada, T., Furutani, M., Ishigami, S., Nowano, M., Mizumoto, M., Fukumoto, M. and Imamura, M.: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology, 24: 316, 1996.
15. Garbisa, S., Pozzatti, R., Muschel, R. J., Saffiotti, U., Ballin M., Goldfarb, R. H., Khoury, G. and Liotta, L. A.: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transaction with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res., 47: 1523, 1987.
16. Spruck III, C. H., Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S., Cots, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G. and Jones, P. A.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784, 1994.
17. Grignon, D. J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F. and Pontes, J. E.: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res., 56: 1654, 1996.
18. Rao, J. S., Steck, P. A., Mohanam, S., Stetler-Stevenson, W. G., Liotta, L. A. and Sawaya, K.: Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res., 53: 2208, 1993.
19. Ueda, Y., Imai, K, Tsuchiya, H., Fujimoto, N., Nakanishi, I., Katsuda, S., Seiki, M. and Okada, Y.: Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am. J. Pathol., 148: 611, 1996.
20. Naruo, S., Kanayama, H., Takigawa, H., Kagawa, S., Yamashita, K. and Hayakawa, T.: Serum levels of a tissue inhibitor of metalloproteinase-1 (TIMP-1 in bladder cancer patients. Int. J. Urol., 1: 228, 1994.
21. Wojtowicz-Praga, S. M., Dickson, R. B. and Hawkins, M. J.: Matrix metalloproteinase inhibitors. Invest. New Drugs, 15: 61, 1997.